Hamps Bio Limited (BOM:544312)
India · Delayed Price · Currency is INR 24.50
0.00 (0.00%)
At close: Oct 16, 2026
Hamps Bio Revenue
In the fiscal year ending March 31, 2026, Hamps Bio had annual revenue of 84.75M INR with 27.08% growth. Hamps Bio had revenue of 44.83M in the half year ending March 31, 2026. That makes Hamps Bio the 43,787th largest company in the world by revenue and 4,564th in India.
Revenue
84.75M
Revenue Growth
+27.08%
P/S Ratio
2.52
Revenue / Employee
1.66M
Employees
51
Market Cap
213.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 84.75M | 18.06M | 27.08% |
| Mar 31, 2025 | 66.69M | 1.94M | 2.99% |
| Mar 31, 2024 | 64.75M | 8.97M | 16.08% |
| Mar 31, 2023 | 55.78M | 2.38M | 4.45% |
| Mar 31, 2022 | 53.40M | 15.18M | 39.71% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Welcure Drugs and Pharmaceuticals | 3.66B |
| Add-Shop E-Retail | 1.71B |
| Deccan Health Care | 818.34M |
| Walpar Nutritions | 789.14M |
| Gujarat Terce Laboratories | 456.22M |
| Unjha Formulations | 152.79M |
| Zenith Healthcare | 108.46M |
| Norris Medicines | 76.00M |